GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lombard Medical Technologies PLC (LSE:LMT) » Definitions » Net Income

Lombard Medical Technologies (LSE:LMT) Net Income : £-8.29 Mil (TTM As of Dec. 2012)


View and export this data going back to . Start your Free Trial

What is Lombard Medical Technologies Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Lombard Medical Technologies's Net Income for the six months ended in Dec. 2012 was £-8.29 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2012 was £-8.29 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Lombard Medical Technologies's Earnings per Share (Diluted) for the six months ended in Dec. 2012 was £-0.41.


Lombard Medical Technologies Net Income Historical Data

The historical data trend for Lombard Medical Technologies's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lombard Medical Technologies Net Income Chart

Lombard Medical Technologies Annual Data
Trend Sep02 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.74 -6.18 -7.77 -10.07 -8.29

Lombard Medical Technologies Semi-Annual Data
Sep02 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.74 -6.18 -7.77 -10.07 -8.29

Lombard Medical Technologies Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Lombard Medical Technologies's Net Income for the fiscal year that ended in Dec. 2012 is calculated as

Net Income(A: Dec. 2012 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-8.642+0.35+0+-0.00099999999999945
=-8.29

Lombard Medical Technologies's Net Income for the quarter that ended in Dec. 2012 is calculated as

Net Income(Q: Dec. 2012 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-8.642+0.35+0+-0.00099999999999945
=-8.29

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income for the trailing twelve months (TTM) ended in Dec. 2012 was £-8.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lombard Medical Technologies  (LSE:LMT) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Lombard Medical Technologies's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2012 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Lombard Medical Technologies Net Income Related Terms

Thank you for viewing the detailed overview of Lombard Medical Technologies's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Lombard Medical Technologies (LSE:LMT) Business Description

Traded in Other Exchanges
N/A
Address
Lombard Medical Technologies PLC is engaged in the design and development of endovascular stent grafts, their manufacture, and commercialization either directly through the group's own sales force or through a network of local distributors supported by clinical specialists from Lombard Medical. The principal product, the AorfixT AAA stent graft has European CE mark approval for use in patients with high-angle-neck aneurysms of up to 90 degrees. The group has operations in United Kingdom and United States of America.